MAIA Latest Press Releases

-- October 7, 2026 --

MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer Globe Newswire 8:15 AM

-- October 1, 2026 --

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) Globe Newswire 8:00 AM

-- September 23, 2026 --

MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal Globe Newswire 9:17 AM

-- September 22, 2026 --

MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer Globe Newswire 8:47 AM

-- September 16, 2026 --

MAIA Biotechnology Doses First U.S. Patient in Ongoing Phase 2 Non-Small Cell Lung Cancer Clinical Trial Globe Newswire 8:15 AM

-- September 15, 2026 --

MAIA Biotechnology Announces Open Market Purchases of Company Stock by Long-Standing Board Member and CEO Globe Newswire 8:15 AM

-- September 10, 2026 --

MAIA Biotechnology Delivers Oral and Poster Presentations Showcasing Next-Generation Telomere-Targeting Cancer Therapies at IRT 2026 Globe Newswire 8:15 AM

-- August 17, 2026 --

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) Globe Newswire 8:00 AM

-- July 8, 2026 --

MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial Globe Newswire 9:45 AM

-- June 25, 2026 --

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer Globe Newswire 8:08 AM

-- June 18, 2026 --

MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University Globe Newswire 8:30 AM

-- June 10, 2026 --

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial Globe Newswire 9:15 AM

-- June 4, 2026 --

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial Globe Newswire 9:45 AM

-- June 3, 2026 --

MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion Globe Newswire 9:45 AM

-- June 2, 2026 --

MAIA Biotechnology Announces Open Market Purchases by CEO and Director Globe Newswire 9:45 AM

-- June 1, 2026 --

MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes